A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

BACKGROUND: Crizotinib is the approved treatment for advanced non-small cell lung cancers (NSCLCs) of anaplastic lymphoma kinase (ALK) fusion. Failure of crizotinib treatment frequently involves drug intolerance or resistance. Comparison of using second-generation ALK inhibitors in this setting rema...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:BMC Cancer
Główni autorzy: Kuo, Chih-Hsi Scott, Tung, Pi-Hung, Huang, Allen Chung-Cheng, Wang, Chin-Chou, Chang, John Wen-Cheng, Liu, Chien-Ying, Chung, Fu-Tsai, Fang, Yueh-Fu, Guo, Yi-Ke, Yang, Cheng-Ta
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2021
Hasła przedmiotowe:
Research Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7988977/
https://ncbi.nlm.nih.gov/pubmed/33761908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08005-1
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy